Ebola Virus - Blog Visitor Doctor Elohor Proposes Drug Treatment.

-ATTENTION PRESIDENT JONATHAN OF NIGERIA.

-ATTENTION HEALTH MINISTER 

-ATTENTION ALL GOVERNORS.

-ATTENTION INTERESTED HEALTH BODIES.

I am so pissed with Maurice Iwuh and his office!...Yes,i say so because they contacted me and i gave them Elohor's contact but they did not reach out to her.This Lady has been making frantic efforts to tell that she has a possible cure but no one is hearing her out but they are spending monies on monitoring people and not finding a cure.
Is is because she is a woman or because she is Nigerian?will they take this more serious if she was an expatriate doctor?Hissssss
Elohor is desperate to show how her proposal works so she has sent a little bit of what she proposes...This is just a tip of what she has....if no one contacts her and Ebola takes over Nigeria,then so be it!

THERAPEUTIC TRIALS FOR DRUG TREATMENT OF EBOLA VIRUS INFECTION

The Ebola virus (EBOV) belongs to a family of three very virulent viruses known as the filoviruses (Filoviridae). The Filoviridae is comprised of Ebola, Marburg and the Cuevavirus.  Although differing in genome structure and areas of endemicity (where they are found), the filoviruses produce similar patterns of virulence and clinical manifestations.                                    

Infection with either Ebola or Marburg virus results in a spectrum of disease including the “viral hemorrhagic fevers.” 

The virus is very pathogenic, and known to survive up to 3hours on contaminated surfaces, lasting longer within fluid medium. Between 60-90% of persons who acquire the disease are likely to die from its complications.

Routes of Infection and Mode of Transmission.

The Ebola virus enters the human population through contact with infected animals. Several animals have been implicated in Africa; including chimpanzees, gorillas, fruit bats (known reservoir), monkeys, forest antelope and porcupines. Some of these are commonly consumed as “bush meat.” 

Infection occurs through direct contact with the body fluids (blood and secretions {saliva, mucus, urine, semen and stool}) of an infected animal and can then be spread from person to person. 

The known modes of transmission are outlined below:

• Animal to Person transmission (e.g hunters; butchering and consuming infected meat)
• Person to person (including contact with sick persons, corpses and sexual intercourse)
• Contact with fomites (beddings, medical devices, syringes, utensils, etc.)

Through a review of scientific materials and laboratory researches by peer scientists spanning over two decades, I found that EBOV displayed striking bio-molecular, chemical and physical similarities with HIV-1 and the orthomyxoviridae (influenza virus). These organisms have existing and effective therapeutic compounds which can be exploited by immunological mechanisms to suppress EBOV at corresponding points of vulnerability.

Some vulnerable and exploitable points of activity within the virus include its genome activity, membrane/extracellular binding, mechanism of immune system disruption, and intracellular/ lysosomal binding.  Pharmacological agents aimed at inhibiting these processes will successfully hinder viral activity, replication and virulence, curbing the disease.                                                                                                                                    

This may be one of the major ways to reduce the incidence of the disease among contacts of already infected persons, suppress infection in persons within the incubation period, and support therapy of patients in the early phase of the disease. Replacing or boosting immune factors (interleukins 6 and -1B) also promises to be helpful in increasing survival rates of infected persons. Patients being observed in isolation may benefit from receiving the appropriate immune factors and an existing influenza vaccine can be exploited and modified to elicit immunological protection among health workers exposed to infected patients.

Two classes of antiretroviral agents (protease and nucleoside reverse transcriptase inhibitors) are capable of mimicking and eliciting similar responses within the Ebola virus as they do within HIV-1. Protease inhibitors will block the cleavage of EBOV’s membrane protein (GP) preventing binding to intracellular lysosomes where it undergoes replication. Ritonavir or the more specific Giardia cysteine protease inhibitors are highly promising pharmacological agents for this therapeutic trial.

Unlike the HIV-1 virus, the Ebola virus does not possess a reverse transcriptase enzyme. Instead, one of its proteins, VP 30, acts both as a transcription or replicating factor.  However, just like in HIV-1, nucleoside inhibitors can act as DNA analogues, become phosphorylated by similar kinases, and incorporate into a replicating chain, halting this vital process. 

The result is a decreased viral load within the patient which not only promotes survival but also decreases the ability to infect others. Notably, only a few specific drugs within this group demonstrate the right relationship with the Ebola virus. A good example is Ribavirin.

Effective and practical combinations of these agents are essential to maintain efficacy. All researched drug groups have been approved by the United States FDA, NAFDAC and other relevant health bodies. It is imperative to take advantage of science and the potential safety offered by these groups of drugs to treat the suffering and protect the uninfected.                                                         

It is worth mentioning that some organisms retain certain distinct biochemical properties that may cause them to behave erratically and block beneficial immunological processes. In this case, a clear understanding of the EBOV’s biochemistry and points of vulnerability as outlined in this review outcome, will guide swift production of vaccines, and manipulation of already existing chemotherapeutics so that a quick and lasting solution can be found.                                                          

 This may be the best way to halt the potential catastrophe.

Elohor (Okpeva) Effiong

B.SC; MBBS (PHC); PgCs; MPH (Johns Hopkins) 

                                                                                        

 Expert,Health in Crisis and Humanitarian Assistance                                                                                                                            

International Health.

(Complete scientific review to be disclosed to interested academic peers and other health bodies involved in Ebola management)

Disclaimer: I do not sell nor intend to sell any pharmaceutical agent. This is not a sponsored article but a summary of diligent literature review and insight, citing over 40 articles from peer journal

*AMERICA STAY OUTTA THIS.....STAY OUTTA THIS!!!